Skip to content

Pulmonary Valve Replacement in Large Right Ventricular Outflow Tract

Pulmonary Valve Replacement : Study of Comparison Between a Standard Surgical Approach With Extracorporeal Circulation and an Off-pump Hybrid Strategy.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00259207
Enrollment
8
Registered
2005-11-29
Start date
2005-12-31
Completion date
2009-05-31
Last updated
2009-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Valve Insufficiency

Keywords

Pulmonary valve regurgitation, Valve replacement, Hybrid procedure

Brief summary

The purpose of this study is to compare 2 techniques of pulmonary valve replacement in patients with a large right ventricular outflow tract: a standard surgical treatment using cardiopulmonary bypass versus a medico-surgical hybrid strategy without extracorporeal circulation.

Detailed description

Pulmonary regurgitation is a common complication late after complete correction of a tetralogy of Fallot. It progressively leads to a right ventricular dilatation that has been strongly associated with ventricular arrhythmia, sudden death and right ventricular insufficiency. Pulmonary valve replacement reduces the rate of complications but the precise timing for this procedure remains unknown. Moreover, pulmonary valve replacement, even before the occurrence of symptoms, doesn't allow for a total recovery in all patients. Reasons are not known, but cardiopulmonary bypass as well as late referral to surgery have been incriminated to explain the persistence of right ventricular dysfunction after surgical valvular. Therefore, a strategy avoiding cardiopulmonary bypass could potentially preserve the right ventricular function and in the meantime reduce the hospitalisation length and morbid-mortality. For the last six years, we and others have developed a technique of percutaneous pulmonary valve implantation. Encouraging results were reported in the treatment of failing right ventricular to pulmonary artery conduit, but presents indications are limited and the innovative technique could not be offered to most of patients requiring pulmonary valve replacement. In particular, to date, conventional surgery is the only approach for patients with large pulmonary trunk over 22 mm in diameter. We had the idea of collaborating with the surgeons to try to improve the outcome of valvular in these patients. We would like to investigate a hybrid strategy in those patients with large right ventricular outflow tract inaccessible to solely transcatheter technique. The studied technique will associate a surgical pulmonary artery banding without cardiopulmonary bypass immediately followed by a transventricular or a transvenous pulmonary valve insertion using a conventional valved stent. The purpose of this randomized study is to evaluate benefits and risks of the medico-surgical hybrid strategy, and to compare both strategies hybrid approach and conventional surgery with extracorporeal circulation in term of right ventricular function recovery.

Interventions

PROCEDUREmedical surgery hybride

medical surgery hybride

PROCEDUREPulmonary valve insertion

Pulmonary valve insertion

Sponsors

Hôpital Necker-Enfants Malades
CollaboratorOTHER
European Georges Pompidou Hospital
CollaboratorOTHER
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. Patient with surgical indication of pulmonary valve replacement for significant pulmonary regurgitation 2. Pulmonary trunk diameter \> 22mm 3. Age \> 5 years old or weight \> 20kg 4. Acceptance of protocol 5. Social regimen security

Exclusion criteria

1. No indication of pulmonary valve replacement 2. Age \< 5 years old or weight \< 20kg 3. Extra-cardiac disease with a vital prognosis under 6 months 4. Heparin and contrast allergy 5. Clinical or biological signs of infection 6. Pregnancy 7. Patients in emergency state 8. Patients included in an another research protocol during the last months

Design outcomes

Primary

MeasureTime frame
Right ventricular functionduring the study

Secondary

MeasureTime frame
Morbidity and mortalityduring the study
Length of stayduring the study

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026